Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

To compare the rapidity of metabolic decompensation after interruption of CSII between human regular and lispro insulin and to compare these two insulins in the correction of the hyperglycemia and ketosis of mildly decompensated IDDM.

Lispro insulin may be especially useful for insulin pump therapy (continuous subcutaneous insulin infusion [CSII]).

Who Took Part

According to the abstract, 18 patients were involved.

The age groups tagged for this paper are adults, both men and women.

The study consisted of two phases: 1) an insulin interruption phase, in which the basal insulin infusion was stopped (at 0300) and plasma insulin, glucose, and beta-O-hydroxybutyrate (beta-OHB) were measured every 15-60 min for 6 h after interruption of the insulin infusion and 2) an insulin replacement phase, which involved measuring plasma insulin, glucose, and beta-OHB for 2 h after a single injection of either human regular or lispro insulin to correct the hyperglycemia and ketosis that developed during the first phase of the study.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

All were being treated with CSII (nine with human regular and nine with lispro insulin).

What Was Measured

Topics PubMed links to this paper include Acute Disease, Blood Glucose, Diabetes Mellitus, Type 1, Drug Therapy, Hydroxybutyrates, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized study of Insulin Lispro in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.